AbbVie (ABBV) cash: $5.2B
AbbVie held $5.2B in cash and cash equivalents on Dec 31, 2025, down 5.3% from $5.5B a year earlier.
From AbbVie's filings with the SEC · Read the filing · ABBV stock page
AbbVie cash by year
#121 of 4,171 US companies by cash · See the full ranking
| Year ended | Cash | Change |
|---|---|---|
| Dec 31, 2025 | $5.2B | -5% |
| Dec 31, 2024 | $5.5B | -57% |
| Dec 31, 2023 | $12.8B | +39% |
| Dec 31, 2022 | $9.2B | -6% |
| Dec 31, 2021 | $9.7B | – |
Cash of similar companies
Companies in the same industry as AbbVie, by SEC industry code, with the closest cash. Each name opens the same page for that company.
| Company | Cash, latest year | Year ended |
|---|---|---|
| Abbott Laboratories | $8.5B | Dec 31, 2025 |
| Eli Lilly | $7.3B | Dec 31, 2025 |
| AbbVie | $5.2B | Dec 31, 2025 |
| Vertex Pharmaceuticals Inc / Ma | $5.1B | Dec 31, 2025 |
| BeOne Medicines | $4.5B | Dec 31, 2025 |
| TEVA Pharmaceutical Industries | $3.6B | Dec 31, 2025 |
| Regeneron Pharmaceuticals | $3.1B | Dec 31, 2025 |
Questions and answers
What is AbbVie's cash?
AbbVie held $5.2B in cash and cash equivalents on Dec 31, 2025, down 5.3% from $5.5B a year earlier.
Numbers as reported in AbbVie's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology